Literature DB >> 17083554

Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Faik Gelisken, Focke Ziemssen, Michael Voelker, Karl U Bartz-Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17083554     DOI： 10.1111/j.1600-0420.2006.00765.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN： 1395-3907


× No keyword cloud information.
  9 in total

1.  Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration.

Authors:  Gary K Y Lee; Timothy Y Y Lai; Wai-Man Chan; Dennis S C Lam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.117

2.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.

Authors:  Alexa Karina Klettner; Marie-Luise Kruse; Tim Meyer; Daniela Wesch; Dieter Kabelitz; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-14       Impact factor: 3.117

4.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

Review 5.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Retinal pigment epithelial tears following ranibizumab therapy for fibrovascular retinal pigment epithelial detachment due to occult age-related macular degeneration.

Authors:  Małgorzata Figurska
Journal:  Med Sci Monit       Date:  2012-01

7.  RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD.

Authors:  Maria Andreea Gamulescu; Carsten Framme; Helmut Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-21       Impact factor: 3.535

8.  Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).

Authors:  Focke Ziemssen; Christoph M Deuter; Nicole Stuebiger; Manfred Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-12       Impact factor: 3.535

Review 9.  Bevacizumab: off-label use in ophthalmology.

Authors:  Salvatore Grisanti; Focke Ziemssen
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.